Publications Archive - KalVista Pharmaceuticals

Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials

Mauro Cancian, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Emel Aygören-Pürsün, Sorena Kiani-Alikhan

Presented at Italian Network for Hereditary and Acquired Angioedema (ITACA) Meeting; March 27-29, 2025; Palermo, Italy

Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S

Jonathan Bernstein, Emel Aygören-Pürsün, Vesna Grivcheva-Panovska, Inmaculada Martinez-Saguer, Danny Cohn, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Henriette Farkas

Presented at American Academy of Allergy, Asthma, and Immunology/World Allergy Organization (AAAAI/WAO) Joint Conference; February 28-March 3, 2025; San Diego, California

On-demand Treatment Of Hereditary Angioedema Attacks With Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S

Danny Cohn, Aharon Kessel, Tamar Kinaciyan, Rand Arnaout, Jonathan Peter, H James Wedner, Emel Aygören-Pürsün, Jonathan Bernstein, Henriette Farkas, William Lumry, Marcus Maurer, Marc Riedl, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya, Fotios Psarros

Presented at American Academy of Allergy, Asthma, and Immunology/World Allergy Organization (AAAAI/WAO) Joint Conference; February 28-March 3, 2025; San Diego, California

Safety and Effectiveness of Sebetralstat in Patients with Hereditary Angioedema Receiving Long-term Prophylaxis: Interim Analysis from the KONFIDENT-S Open-label Study

Marc Riedl, Jonathan Bernstein, H Henry Li, Michael Manning, Jason Raasch, James Hao, Michael Smith, Paul Audhya, William Lumry

Presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting; February 9-13, 2025; Waimea, Hawaii

Sebetralstat for Treatment of Hereditary Angioedema Attacks in Patients Receiving Berotralstat: Interim Analysis from the KONFIDENT-S Open-label Study

Michael Manning, Marc Riedl, Raffi Tachdijan, H Henry Li, H James Wedner, Daniel Soteres, James Hao, Michael Smith, Paul Audhya, Tamar Kinaciyan

Presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting; February 9-13, 2025; Waimea, Hawaii

Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials

Patrick Yong, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Emel Aygören-Pürsün, Sinisa Savic, Sorena Kiani-Alikhan

Presented at British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference; December 9-10, 2024; Birmingham, United Kingdom

Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial

Timothy Craig, Jonathan Bernstein, Hilary Longhurst, James Hao, Michael Smith, Paul Audhya, Christopher Yea, Marcus Maurer

Presented at American College of Allergy, Asthma, and Immunology (ACAAI) Conference; October 24-28, 2024; Boston, Massachusetts

Indirect Treatment Comparison of Oral Sebetralstat and Intravenous rhC1-INH as On-demand Treatments for Hereditary Angioedema

H Henry Li, Markus Magerl, Timothy Craig, Michael Manning, Noemi Hummel, Alice Wang, Paul Audhya, Jonathan Bernstein

Presented at American College of Allergy, Asthma, and Immunology (ACAAI) Conference; October 24-28, 2024; Boston, Massachusetts

On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebetralstat: Pooled Analysis from KONFIDENT and KONFIDENT-S

Emel Aygören-Pürsün, Jonathan Bernstein, William Lumry, Paul Audhya, James Hao, Michael Smith, Christopher Yea, Marc Riedl

Presented at American College of Allergy, Asthma, and Immunology (ACAAI) Conference; October 24-28, 2024; Boston, MA

Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial

William Lumry, Danny Cohn, Jonathan Bernstein, Paul Audhya, James Hao, Michael Smith, Christopher Yea, Marc Riedl

Presented at American College of Allergy, Asthma, and Immunology (ACAAI) Conference; October 24-28, 2024; Boston, Massachusetts

Impact of Oral Sebetralstat on Hereditary Angioedema Attack-associated Anxiety: Analysis From the Phase 3 KONFIDENT Trial

Marcus Maurer, Danny Cohn, Jonathan Bernstein, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Paul Audhya, Christopher Yea, Emel Aygören-Pürsün

Presented at the ACARE Global Angioedema Forum 2024; October 4-5, 2024; Copenhagen, Denmark

KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Populations

Andrea Zanichelli, Emel Aygören-Pürsün, Jonathan Bernstein, Henriette Farkas, William Lumry, Marcus Maurer, Marc Riedl, James Hao, Michael Smith, Paul Audhya, Christopher Yea, Danny Cohn

Presented at the ACARE Global Angioedema Forum 2024; October 4-5, 2024; Copenhagen, Denmark

KONFIDENT-S Interim Analysis: Sebetralstat for Hereditary Angioedema Attacks Including Laryngeal

Henriette Farkas, Marc Riedl, Emel Aygören-Pürsün, William Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya, Jonathan Bernstein, Marcus Maurer, Danny Cohn

Presented at Bradykinin Symposium; September 4-6, 2024; Berlin, Germany

Pooled Sebetralstat Placebo-controlled Efficacy for On-demand Treatment of Hereditary Angioedema

Marcus Maurer, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya, Sorena Kiani-Alikhan, Emel Aygören-Pürsün

Presented at Bradykinin Symposium; September 4-6, 2024; Berlin, Germany

Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema

Emel Aygören-Pürsün, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, Samuel Owiredu-Yeboa, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Sorena Kiani-Alikhan, Marcus Maurer

Presented at Bradykinin Symposium; September 4-6, 2024; Berlin, Germany

Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of the Open-label KONFIDENT-S Trial

Henriette Farkas, Marc Riedl, Emel Aygören-Pürsün, William Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya, Jonathan Bernstein, Marcus Maurer, Danny Cohn

Presented at European Academy of Allergy & Clinical Immunology (EAACI) Congress; May 31 - June 3, 2024; Valencia, Spain

Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: US Subgroup Analysis from the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial

Daniel Soteres, Marc Riedl, William Lumry, Paula Busse, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya, Jonathan Bernstein

Presented at the Eastern Allergy Conference (EAC); May 30 - June 2, 2024; Palm Beach, Florida

KONFIDENT Phase 3 Trial Global Expansion: Sebetralstat Pharmacokinetics and Pharmacodynamics in Japanese and Chinese Adults

Daisuke Honda, Matthew Iverson, Erik Hansen, Sally Hampton, Stanford Jhee, Esther Yoon, Paul Audhya, Michael Smith, Christopher Yea, Michihiro Hide

Presented at Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) International Conference; October 23-26, 2023; Singapore

Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults

Michihiro Hide, Matthew Iverson, Stanford Jhee, Erik Hansen, Edward Duckworth, Sally Hampton, Esther Yoon, Daisuke Honda

Presented at European Academy of Allergy & Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany

Short-term Prophylaxis with Sebetralstat, an Investigational On-demand Treatment for Hereditary Angioedema, in KONFIDENT-S

Jonathan Bernstein, Marc Riedl, William Lumry, Paul Audhya, Michael Smith, Christopher Yea

Presented at European Academy of Allergy & Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Hilary Longhurst, Michael Smith, Christopher Yea, Paul Audhya

Presented at the Eastern Allergy Conference (EAC); June 1-4, 2023; Palm Beach, Florida

Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S

Matthew Iverson, Edward Duckworth, Erik Hanson, Sally Hampton, Michael Smith, Paul Audhya, Christopher Yea

Presented at 13th C1-Inhibitor Deficiency & Angioedema (C1-INH) Workshop; May 4-7, 2023; Budapest, Hungary

Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers

Michael Smith, Matthew Iverson, Erik Hansen, Paul Audhya, Christopher Yea

Presented at American Academy of Allergy, Asthma, and Immunology (AAAAI) Conference; February 24-27, 2023; San Antonio, Texas

Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial

Jonathan Bernstein, Marc Riedl, William Lumry, Paul Audhya, Michael Smith, Christopher Yea

Presented at American Academy of Allergy, Asthma, and Immunology (AAAAI) Conference; February 24-27, 2023; San Antonio, Texas

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema

Emel Aygören-Pürsün, Andrea Zanichelli, Danny Cohn, Paul Audhya, Peter Williams, Christopher Yea, Michael Smith

Presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting; February 5-9, 2023; Kamuela, Hawaii

Pharmacokinetic, Pharmacodynamic, and Safety Profile in Healthy Japanese and White Adults: Results from Phase 1, Randomized, Double-blind, Placebo-controlled Trial

Matthew Iverson, Stanford Jhee, Erik Hansen, Edward Duckworth, Sally Hampton, Esther Yoon

Presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting; February 5-9, 2023; Kamuela, Hawaii

Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks

Marc Riedl, Danny Cohn, Emel Aygören-Pürsün, Andrea Zanichelli, Henriette Farkas, Jonathan Bernstein, William Lumry, Michael Smith, Christopher Yea, Paul Audhya

Presented at the 2022 HAEi Global Leadership Workshop; October 6-9, 2022; Frankfurt, Germany

Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Volunteers and Patients with Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients

Michael Smith, Trudy Rodgers, Johannah Sharman, Peter Mutch, Raffi Tachdjian, Sinisa Savic, Colm Farrell

Presented at European Academy of Allergy & Clinical Immunology (EAACI) Congress; July 1–3, 2022; Prague, Czech Republic

Agreement Between Improvements in Patient Global Assessment of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial with Sebetralstat (KVD900) in Patients with Hereditary Angioedema

Paul Audhya, Michael Smith, Peter Williams, Christopher Yea, Danny Cohn

Presented at the Eastern Allergy Conference (EAC); June 2-5, 2022; Palm Beach, Florida

Agreement of Patient Global Assessment of Change With Attack Resolution or Use of Rescue Medication in Patients with Hereditary Angioedema

Paul Audhya, Peter Williams, Christopher Yea, Danny Cohn

Presented at American Academy of Allergy, Asthma, and Immunology (AAAAI) Conference; February 25-28, 2022; Phoenix, Arizona

SELECT PUBLICATIONS

About

Science

Pipeline

Careers

Contact